Description
Irinotecan Medaс for Infusions 20 mg/ml, 5 ml (100 mg)
Composition
Active Ingredient: Irinotecan hydrochloride trihydrate. Inactive ingredients may include ethanol, glycocholic acid, and water for injections.
Mechanism of Action
Irinotecan is a topoisomerase I inhibitor that exerts its antitumor effects by disrupting DNA replication and cell division processes, leading to cell death. This mechanism is particularly effective against various solid tumors, such as colorectal and lung cancers.
Pharmacological Properties
Irinotecan Medaс demonstrates potent antineoplastic activity by inhibiting topoisomerase I, a crucial enzyme involved in DNA synthesis. This inhibition results in DNA damage and ultimately cell death, making it an important agent in cancer therapy.
Indications for Use
Irinotecan Medaс is indicated for the treatment of colorectal cancer and small cell lung cancer. It is typically administered in combination with other chemotherapeutic agents as part of a comprehensive treatment regimen.
Contraindications
Use of Irinotecan Medaс is contraindicated in patients with a known hypersensitivity to irinotecan or any of the inactive ingredients. It should also be avoided in individuals with severe bone marrow suppression to prevent exacerbation of hematological complications.
Side Effects
Common side effects of Irinotecan Medaс may include severe diarrhea, myelosuppression, nausea, and vomiting. Patients undergoing treatment should be closely monitored for these adverse reactions to ensure timely intervention and management.
Usage Instructions
Irinotecan Medaс should be administered intravenously by healthcare professionals experienced in chemotherapy administration. The dosage is determined based on the patient’s body surface area and the specific treatment protocol. It is essential to follow the recommended infusion rate and duration for optimal therapeutic outcomes.
Benefits Compared to Analogues
Irinotecan Medaс offers superior efficacy in the treatment of colorectal and small cell lung cancers compared to some traditional chemotherapeutic agents. Its mechanism of action and proven clinical outcomes make it a valuable addition to cancer therapy protocols.
Suitable Patient Groups
Irinotecan Medaс is suitable for adult patients with colorectal or small cell lung cancer who require systemic chemotherapy. Special consideration should be given to individual patient characteristics, such as age, comorbidities, and overall health status, to determine the appropriateness of treatment.
Storage and Shelf Life
It is important to store Irinotecan Medaс as directed in the package insert to maintain its stability and efficacy. The product should be kept out of reach of children and protected from direct sunlight to prevent degradation. Check the expiration date before use and discard any expired medication appropriately.
Packaging Description
Irinotecan Medaс is typically supplied in vials containing 5 ml of a 20 mg/ml solution (100 mg total). The packaging is designed to ensure the integrity and sterility of the product until the time of administration. Each vial should be inspected for any signs of damage or tampering before use.
Clinical Evidence and Proven Effectiveness
Pharmacological studies have confirmed the efficacy of Irinotecan in inhibiting tumor growth and improving survival outcomes in patients with advanced colorectal cancer. Clinical trials have demonstrated its effectiveness in combination therapies for small cell lung cancer, highlighting its role as a key component in modern oncology treatment regimens.
